Physician profile
Charles Cho
NPI 1053512566
$25,917.34
in general payments reported to CMS, 2019-2025
46 companies · $929 in 2025
The $929 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $1,989 · 2021: $2,363 · 2022: $1,471 · 2023: $756 · 2024: $1,035 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.03 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8,286.33 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $5,364.39 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $3,569.28 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $1,168.01 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,145.56 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $718.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $547.54 | 2024-2025 | |
| Amarin Pharma, INC. | $519.99 | 2019-2023 | |
| Lilly USA, LLC | $439.85 | 2019-2022 | |
| Pfizer INC. | $355.08 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $326.53 | 2019-2025 | Jynarque, Rexulti |
| Abbvie INC. | $322.59 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $269.96 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $255.05 | 2022-2025 | Tarpeyo |
| Radius Health, INC. | $246.78 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.